Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo

Authors: Ju-Feng Zhang, Fang Wei, Hui-Ping Wang, Hui-Ming Li, Wei Qiu, Peng-Kang Ren, Xia-Fang Chen, Qian Huang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

Non-small cell lung cancer (NSCLC) is the leading cause of cancer related mortality, any improvements in therapeutic strategies are urgently required. In this study we generated a novel 'suicide gene' armed oncolytic adenoviral vector and investigated its antitumor effect both in vitro and in vivo.

Methods

Since the up-regulated expression of human telomerase reverse transcriptase (hTERT) is a hallmark of alltypes of NSCLC, we chose hTERT promoter to transcriptionally control E1A gene expression to obtain adenoviral replication in NSCLC. In order to further enhance anti-tumor effect of this oncolytic adenoviral vector, we inserted a 'suicide gene' i.e. Herpes Simplex Virus Thymidine Kinase (HSV-TK) into oncolytic adenoviral vector to engineer a novel armed oncolytic adenoviral vector 'Ad.hTERT-E1A-TK'.

Results

Ad.hTERT-E1A-TK efficiently killed different types of tumor cells including two types of NSCLC cells in vitro, causing no damage to normal primary fibroblasts. Furthermore, Ad.hTERT-E1A-TK infection combined with administration of prodrug gancyclovir (GCV) resulted in more potent cytotoxicity on NSCLC cells, and synergistically suppressed human NSCLC tumor growth in nude mice.

Conclusion

The results from this study showed that Ad.hTERT-E1A-TK/GCV could be a potent but safe anti-tumor strategy for NSCLC biotherapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA: Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer. 2006, 8: 195-202. 10.3816/CLC.2006.n.047.CrossRef Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA: Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer. 2006, 8: 195-202. 10.3816/CLC.2006.n.047.CrossRef
2.
go back to reference Rossi A, Maione P, Colantuoni G, Ferrara C, Rossi E, Guerriero C, Nicolella D, Falanga M, Palazzolo G, Gridelli C: Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Curr Drug Discov Technol. 2009, 6: 91-102. 10.2174/157016309788488339.CrossRef Rossi A, Maione P, Colantuoni G, Ferrara C, Rossi E, Guerriero C, Nicolella D, Falanga M, Palazzolo G, Gridelli C: Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Curr Drug Discov Technol. 2009, 6: 91-102. 10.2174/157016309788488339.CrossRef
3.
go back to reference Ricciardi S, Tomao S, Marinis F: Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009, 10: 28-35. 10.3816/CLC.2009.n.004.CrossRef Ricciardi S, Tomao S, Marinis F: Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009, 10: 28-35. 10.3816/CLC.2009.n.004.CrossRef
4.
go back to reference Herbst RS, Sandler AB: Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2004, 6: S7-S19. 10.3816/CLC.2004.s.009.CrossRef Herbst RS, Sandler AB: Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2004, 6: S7-S19. 10.3816/CLC.2004.s.009.CrossRef
5.
go back to reference Baumann M, Krause M, Zips D, Petersen C, Dittmann K, Dörr W, Rodemann HP: Molecular targeting in radiotherapy of lung cancer. Lung Cancer. 2004, 45: S187-197. 10.1016/j.lungcan.2004.07.975.CrossRef Baumann M, Krause M, Zips D, Petersen C, Dittmann K, Dörr W, Rodemann HP: Molecular targeting in radiotherapy of lung cancer. Lung Cancer. 2004, 45: S187-197. 10.1016/j.lungcan.2004.07.975.CrossRef
6.
go back to reference Määttä AM, Tenhunen A, Pasanen T, Meriläinen O, Pellinen R, Mäkinen K, Alhava E, Wahlfors J: Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy. Int J Oncol. 2004, 24: 943-949. Määttä AM, Tenhunen A, Pasanen T, Meriläinen O, Pellinen R, Mäkinen K, Alhava E, Wahlfors J: Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy. Int J Oncol. 2004, 24: 943-949.
7.
go back to reference Nemunaitis J, Vorhies JS, Pappen B, Senzer N: 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. Cancer Gene Ther. 2007, 14: 762-763. 10.1038/sj.cgt.7701048.CrossRef Nemunaitis J, Vorhies JS, Pappen B, Senzer N: 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. Cancer Gene Ther. 2007, 14: 762-763. 10.1038/sj.cgt.7701048.CrossRef
8.
go back to reference Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, Bae KH, Jeng MH, Kao C, Gardner T: Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther. 2004, 10: 1051-1058. 10.1016/j.ymthe.2004.08.028.CrossRef Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, Bae KH, Jeng MH, Kao C, Gardner T: Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther. 2004, 10: 1051-1058. 10.1016/j.ymthe.2004.08.028.CrossRef
9.
go back to reference Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS: Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther. 2007, 18: 589-602. 10.1089/hum.2007.002.CrossRef Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS: Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther. 2007, 18: 589-602. 10.1089/hum.2007.002.CrossRef
10.
go back to reference Strazisar M, Mlakar V, Glavac D: The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC). Cell Mol Biol Lett. 2009, 14: 442-4569. 10.2478/s11658-009-0011-7.CrossRef Strazisar M, Mlakar V, Glavac D: The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC). Cell Mol Biol Lett. 2009, 14: 442-4569. 10.2478/s11658-009-0011-7.CrossRef
11.
go back to reference Ji X, Zhang J, Cheng L, Wei F, Li H, Liu X, Chen X, Li C, Wang Y, Huang Q: Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp Eye Res. 2009, 89: 193-199. 10.1016/j.exer.2009.03.007.CrossRef Ji X, Zhang J, Cheng L, Wei F, Li H, Liu X, Chen X, Li C, Wang Y, Huang Q: Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp Eye Res. 2009, 89: 193-199. 10.1016/j.exer.2009.03.007.CrossRef
12.
go back to reference Huang Q, Zhang X, Wang H, Yan B, Kirkpatrick J, Dewhrist MW, Li CY: A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res. 2004, 10: 1439-1445. 10.1158/1078-0432.CCR-03-0122.CrossRef Huang Q, Zhang X, Wang H, Yan B, Kirkpatrick J, Dewhrist MW, Li CY: A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res. 2004, 10: 1439-1445. 10.1158/1078-0432.CCR-03-0122.CrossRef
Metadata
Title
Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo
Authors
Ju-Feng Zhang
Fang Wei
Hui-Ping Wang
Hui-Ming Li
Wei Qiu
Peng-Kang Ren
Xia-Fang Chen
Qian Huang
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-52

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine